us board of directorsmanagement team product portfolio selincrotozadenantsyn120btt1023transparency disclosures investors result centrereleases join mailing list sec filingreports and presentations material archive 201620152014201320122011201020092008200720062005 share information share monitorprice history searchmajor shareholders ownership structurechanges in holdingschanges in number of shares and share capitalauthorisations financial information formulas for the calculation of the key figuresadoption of ifrs standards governance board of directorsmanagement teamcorporate governancepublic insidersshareholders meeting previous shareholders meetings auditorsarticles of associationcompensationrisk managementcode of conductdisclosure policy ir contactslisting prospectustender offer sijoittajat tuloskeskustiedotteet liity tiedotteiden s hk postilistalle sec filingraportit ja esitykset materiaaliarkisto 201620152014201320122011201020092008200720062005 osaketieto osakemonitoriosakkeen hintahistoriahakusuurimmat osakkeenomistajat omistusrakenneliputusilmoituksetmuutokset osakep omassavaltuutukset taloudellista tietoa tunnuslukujen laskentakaavat ifrs tilinp t sk yt nt hallinnointi hallitusjohtoryhm hallinnointiperiaatteetjulkinen sis piiriyhti kokous aikaisemmat yhti kokoukset tilintarkastajatyhti j rjestyspalkitseminenriskienhallintatoimintaohjedisclosure policy sijoittajasuhteetlistalleottoesiteostotarjous media releasespress image galleryscientific papersrecent media coverage careers overviewcurrent openingsrecruitment process developing tomorrow s medicines in neuroscience biotie in brief biotie is a biopharmaceutical company focused on products for neurodegenerative and psychiatric disorders . biotie s development has delivered selincro nalmefene for alcohol dependence which received european marketing authorization in 2013 and is currently being rolled out across europe by partner h. lundbeck a s. the current development products include tozadenant for parkinson s disease which is in phase 3 development and two additional compounds which are in phase 2 development for cognitive disorders including parkinson s disease dementia and primary sclerosing cholangitis psc a rare fibrotic disease of the liver . biotie is a subsidiary of acorda therapeutics inc. acorda and its shares excluding of those owned by acorda are currently subject to a redemption process in accordance with the finnish companies act . updated 30 september 2016 17.06.2016 oyl 18 luvun 5 n mukainen ilmoitus v hemmist osakkeenomistajille lue lis 17.06.2016 notification to shareholders under the companies act chapter 18 section 5 read more 11.03.2016 ostotarjous lue lis 11.03.2016 tender offer read more releases 30.09.2016 acorda gains title to biotie shares and the shares will delist 26.09.2016 arbitral tribunal confirmed acorda s redemption right regarding biotie shares and biotie shares trading has been terminated 26.08.2016 biotie btt1023 receives orphan drug designation in the united states loading ... copyright biotie therapies 2016 legal notice site map contact us print page top of page copyright biotie therapies 2016 legal notice site map contact us print page